Mannosylated T/Tn with Freund's adjuvant induces cellular immunity

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Cancer immunotherapy aims to induce specific immune responses against tumors.
• T/Tn antigen is a target for cancer vaccines.
• Adjuvants are crucial for enhancing vaccine efficacy.

Purpose of the Study:

• To evaluate the efficacy of T/Tn antigen conjugated with oxidized mannan (ox-M) and Freund's adjuvant (FA) in eliciting anti-tumor immunity.
• To assess the impact of different adjuvant formulations on cellular immune responses and tumor protection.

Main Methods:

• Purification of T/Tn antigen from human erythrocytes.
• Immunization of mice with T/Tn antigen alone or with various adjuvant combinations (FA, KLH-T/Tn + FA, ox-M-T/Tn + FA).
• Analysis of cellular immunity (T cells, cytokines, CTL activity) and tumor growth inhibition using techniques like flow cytometry and immunohistochemistry.

Main Results:

• The ox-M-T/Tn + FA vaccine formulation significantly enhanced T/Tn-specific CD3, helper T (Th) cells, and MHC expression.
• This formulation promoted Th1-biased immune responses with high cytotoxic T lymphocyte (CTL) activity.
• Tumor retardation and improved survival rates were observed in mice immunized with ox-M-T/Tn + FA.

Conclusions:

• Oxidized mannan conjugation of T/Tn antigen with Freund's adjuvant creates a potent cancer vaccine.
• This vaccine formulation induces robust cellular immunity and effectively inhibits tumor growth without over-activating the immune system.
• The ox-M-T/Tn + FA vaccine represents a promising strategy for cancer treatment.